Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

  • STATUS
    Recruiting
  • End date
    Jan 1, 2025
  • participants needed
    110
  • sponsor
    Shanghai Zhongshan Hospital
Send
Updated on 15 November 2021
See if I qualify

Summary

This study was a randomized, controled, multicenter, phase II clinical study evaluating the efficacy and safety of fruquintinib as a maintenance therapy following first-line treatment for metastatic colorectal cancer. This study will include the patients with confirmed unresectable metastatic left-sided colon cancer with RAS mutation or right-sided colon cancer who achieved stable disease (SD) or partial response (PR) or complete response (CR) via palliative first-line treatment. It's expected to include 110 patients and they will be randomly stratified at 2:1 into fruquintinib group and observation group based on whether bevacizumab is used and the primary tumor site, using the Interactive Network Response System (IWRS). The random No. corresponds to the respective patient. The enrollment time is expected to be 18 months, followed up for 24 months.

Details
Condition Colorectal Cancer, Colon cancer; rectal cancer, Colon Cancer Screening
Treatment Fruquintinib
Clinical Study IdentifierNCT04296019
SponsorShanghai Zhongshan Hospital
Last Modified on15 November 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

-75 years old (including 18 and 75 years)
Eastern Cooperative Oncology Group-performance score (ECOG PS) 0 or 1
Estimated survival 6 months
Histologically and/or cytologically confirmed metastatic left-sided colon cancer with RAS mutation or right-sided colon cancer, having unresectable metastatic or recurrent foci
Having received first-line systemic anti-tumor therapy for mCRC (chemotherapeutic drugs may include fluorouracil, oxaliplatin, irinotecan, such as XELOX, FOLFOX, FOLFIRI, and can combine or not combine with bevacizumab); achieving RECIST1.1-assessed SD (stable disease) or PR (partial response) or CR (complete response) after 18-24 weeks of first-line treatment
UCG suggesting left ventricular ejection fraction 50%
Having fully understood and voluntarily signed the informed consent

Exclusion Criteria

Absolute neutrophil count (ANC) <1.5109/L, or platelet count <80109/L, or hemoglobin < 9g/dL; it's not allowed to perform blood transfusion within 2 week before enrollment to meet the inclusion criteria
Serum total bilirubin > 1.5 upper limit of normal (ULN); > 2.5 ULN for patients with hepatic metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 ULN, or > 5 ULN for patients with hepatic metastases
Serum creatinine > 1.5 upper limit of normal (ULN), or creatinine clearance < 50mL / min (calculated using Cockcroft-Gault formula)
Partial prothrombin time (APTT) or prothrombin time (PT) > 1.5 times ULN (based on the normal value in the clinical study center)
Clinically significant electrolyte abnormalities
Urine protein 2+ or above, or 24-hour urinary protein quantity 1.0g / 24h
Subjects with dysphagia or known drug absorption disorders
Presence of brain metastasis or leptomeningeal metastasis
The toxicity of previous anticancer treatment has not yet reduced to (NCI CTC AE) level 1, excluding alopecia and oxaliplatin-induced neurotoxicity 2); patients haven't not fully recovered from previous surgery or less than 4 weeks elapsed since previous anticancer treatment or surgery
Patients have clinically detectable second primary malignant tumors at enrollment, or have other malignant tumors (except for well-treated basal cell carcinoma or cervical carcinoma in situ) in the past 5 years
Patients have clinically uncontrolled active infections such as acute pneumonia, hepatitis B or hepatitis C activity (previous history of hepatitis B infection, whether or not under medication control, HBV DNA 104 copies or 2000 IU/ml)
Patients have hypertension that cannot be controlled by a single drug. That is, after single drug treatment, systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg
Patients currently have digestive tract diseases such as duodenal ulcer, ulcerative colitis, intestinal obstruction or other conditions that may cause gastrointestinal bleeding or perforation at the discretion of the investigator; or patients have undergone surgery for intestinal perforation and intestinal fistula but was uncured
Patients have a history of arterial thrombosis or deep vein thrombosis within 6 months prior to enrollment, or patients have bleeding tendency or bleeding history within the 2 months before enrollment, regardless of severity
Patients have a stroke or transient ischemic attack within 12 months prior to enrollment
Skin wounds, surgical sites, trauma site, severe mucosal ulcers or fractures haven't completely healed yet
Patients have acute myocardial infarction, severe/unstable angina, coronary artery bypass grafting or NYHA Class II/more severe cardiac insufficiency within 6 months prior to enrollment
Pregnant or lactating women; or women with potentiality of childbearing have a positive pregnancy test result before the first dose
Patients have any clinical or laboratory abnormalities or compliance problems so that the investigator believes that they are not suitable to participate in this clinical study
Patients have serious psychological or mental abnormalities
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note